Inogen was founded in 2001 to develop products that improve quality of life and increase freedom and mobility for respiratory disease sufferers, predominantly Chronic Obstructive Pulmonary Disease (COPD) patients. COPD is the fourth leading cause of death in the United States, and the only major disease with an ever increasing death rate. By 2020 COPD is predicted to become the third leading cause of death worldwide. COPD affects an estimated 30 million people in the US and over 100 million worldwide.

Supplemental oxygen has been proven to reduce the symptoms of the disease and extend life expectancy of patients with COPD. Despite the clear benefits of oxygen in extending life and maintaining health, many patients find it difficult to comply with therapy because currently available therapy devices inhibit their ability to lead an active life. Today's more active patient is refusing to be restricted in their lifestyle by being tethered to antiquated, stationary machines.

Meeting the needs of today's more ambulatory patient is straining the resources of many respiratory care providers. Current equipment was developed based on paradigms that are now out-of-date; incremental improvements have not sufficiently reduced operating costs for providers. Inogen is developing a line of light-weight, all purpose oxygen therapy devices that effectively integrate into patients' lifestyles and allow providers to improve operating profits.

Inogen has assembled a team of experienced health care entrepreneurs, skilled technologists, well known clinicians and home healthcare veterans to produce innovative solutions to respiratory home healthcare challenges. Inogen's team is passionate about their mission and committed to serving the unique needs of respiratory patients and providers.